ArticleNature biotechnology2026
Precise, minimally evolved adenine base editors generated through mutation reversion analysis.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications.Regenerative therapy · 2026Review
- Engineered Transformer Base Editor with Enhanced Editing Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- On-target and off-target activities of CRISPR therapeutics across scales.Trends in biotechnology · 2026Review
- Precise, minimally evolved adenine base editors generated through mutation reversion analysis.Nature biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The initial development of adenine base editors (ABEs), which facilitate A•T to G•C base pair changes in the genome, used directed evolution to install 14 mutations into the wild-type deaminase TadA, producing the first-of-its-kind editor ABE7.10. Here we study the installed mutations' impacts on TadA fitness using comprehensive reversion analysis and apply our results to engineer more efficient, precise editors. By measuring activity in both human and Escherichia coli host systems, we categorize mutations as critical, dispensable or host dependent. We show that up to five mutations can be reverted back to wild type, generating minimally evolved ABEs (ME-ABEs). ME-ABEs show narrow editing windows (similar to that of ABE7.10) and enhanced on-target editing (matching activities of the high-activity editor variants ABE8e and ABE8.20 in most sequence contexts) and exhibit low levels of guide-RNA-dependent and guide-RNA-independent off-target activity. ME-ABEs efficiently target six sites of clinical interest that had previously proved challenging to edit with ABE7.10, ABE8e or ABE8.20.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.